ADXN NASDAQ
Addex Therapeutics Ltd
1W: -15.9%
1M: -12.8%
3M: -47.0%
YTD: -62.0%
1Y: -67.3%
3Y: -56.4%
5Y: -98.4%
$3.07
+0.09 (+3.02%)
Weekly Expected Move ±14.6%
$2
$3
$3
$4
$4
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$404K
-74.9% ▼
5Y CAGR: -31.9%
Gross Profit
$404K
-74.9% ▼
5Y CAGR: -30.7%
Operating Income
-$3M
-22.8% ▼
Net Income
$7M
+166.8% ▲
EPS (Diluted)
$8.40
+150.0% ▲
EBITDA
-$5M
-112.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $4M | $3M | $1M | $2M | $404K |
| YoY Growth | +30.8% | -19.3% | -51.2% | +13.4% | -74.9% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $4M | $3M | $1M | $2M | $404K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D Expenses | $10M | $9M | $8M | $943K | $435K |
| SG&A Expenses | $6M | $8M | $3M | $2M | $2M |
| Operating Expenses | $16M | $18M | $12M | $4M | $3M |
| Operating Income | -$12M | -$16M | -$11M | -$2M | -$3M |
| Operating Margin | -338.9% | -531.7% | -741.0% | -139.1% | -681.8% |
| Interest Expense | $70K | $63K | $49K | $22K | $4K |
| Income Before Tax | -$13M | -$15M | -$11M | -$3M | -$5M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$13M | -$15M | -$21M | -$11M | $7M |
| Net Margin | -355.9% | -526.4% | -1462.6% | -654.5% | 1746.0% |
| EPS (Diluted) | $-57.60 | $-54.00 | $-55.20 | $-16.80 | $8.40 |
| EBITDA | -$12M | -$15M | -$10M | -$2M | -$5M |
| Shares Outstanding | 222348 | 284330 | 376540 | 619230 | 817606 |